Case study of hypertriglyceridemia from COVID-19 Pfizer-BioNTech vaccination in a patient with familial hypercholesteremia.
Eur Rev Med Pharmacol Sci
; 25(17): 5525-5528, 2021 Sep.
Article
in English
| MEDLINE | ID: covidwho-1417449
ABSTRACT
The Pfizer-BioNTech coronavirus disease 2019 (COVID-19) vaccine is the first novel nucleoside-modified messenger ribonucleic acid (modRNA) vaccine to receive Emergency Use Authorization from the Food and Drug Administration in the United States. It is indicated to be used in patients ≥12 years-of-age as of May 25th, 2021, including populations with high atherosclerotic cardiovascular disease (ASCVD) burden. However, little is known about the potential impact this vaccine may have on serum lipoprotein levels in patients with familial hypercholesteremia (FH), who are predisposed to high ASCVD burden due to elevated low-density lipoprotein cholesterol (LDL-C). We present an interesting case where a patient with heterozygous FH (HeFH) and elevated triglycerides (TG)-controlled for years on medication and apheresis-experienced significantly elevated TG, one day after receiving his second Pfizer-BioNTech COVID-19 vaccine dose. It is not known whether this adverse event may be seen in other FH patients and may be worth assessing in such patients to determine the possibility of a rare adverse reaction from a COVID-19 vaccine.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Hypertriglyceridemia
/
COVID-19 Vaccines
/
Hyperlipoproteinemia Type II
Type of study:
Case report
/
Experimental Studies
/
Observational study
Topics:
Vaccines
Limits:
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Eur Rev Med Pharmacol Sci
Journal subject:
Pharmacology
/
Toxicology
Year:
2021
Document Type:
Article
Affiliation country:
Eurrev_202109_26664
Similar
MEDLINE
...
LILACS
LIS